David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in ...

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast ...

As the FY26 budget is being negotiated, Jennifer Snow, MPA, of NAMI, emphasizes that funds must be directed to programs as ...

The Coalition’s Conversation podcast series is a 3-part discussion on how employers can incorporate glucagon-like peptide-1 ...

The authors of the study and the editorial note that a primary limitation on these findings is the concentration of Medicare ...

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting ...

Explore innovative strategies for team-based care, emphasizing collaboration among diverse healthcare professionals to ...

The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...

Real-world evidence highlights the effectiveness of teclistamab and elranatamab in treating frail multiple myeloma patients, paving the way for future therapies.

Infant protection against respiratory syncytial virus (RSV) by maternal RSV vaccination or receipt of RSV monoclonal antibody ...

NAMI's National Director of Government Relations and Policy, Jennifer Snow, MPA, explains how advocates rallied in support of ...

CKD patients face higher CVD risk, with dyslipidemia differing from the general population, necessitating tailored lipid ...